Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention

NS Yarla, H Gali, G Pathuri, S Smriti, M Farooqui… - Seminars in cancer …, 2019 - Elsevier
Colorectal cancer (CRC) is one of the leading causes of cancer related-deaths. The risk of
development of CRC is complex and multifactorial, and includes disruption of homeostasis …

[HTML][HTML] Guanylyl cyclase C signaling axis and colon cancer prevention

AM Pattison, DJ Merlino, ES Blomain… - World journal of …, 2016 - ncbi.nlm.nih.gov
Colorectal cancer (CRC) is a major cause of cancer-related mortality and morbidity
worldwide. While improved treatments have enhanced overall patient outcome, disease …

[HTML][HTML] The guanylate cyclase C—cGMP signaling axis opposes intestinal epithelial injury and neoplasia

JA Rappaport, SA Waldman - Frontiers in oncology, 2018 - frontiersin.org
Guanylate cyclase C (GUCY2C) is a transmembrane receptor expressed on the luminal
aspect of the intestinal epithelium. Its ligands include bacterial heat-stable enterotoxins …

Guanylyl cyclase C hormone axis at the intersection of obesity and colorectal cancer

ES Blomain, DJ Merlino, AM Pattison, AE Snook… - Molecular …, 2016 - ASPET
Obesity has emerged as a principal cause of mortality worldwide, reflecting comorbidities
including cancer risk, particularly in colorectum. Although this relationship is established …

GUCY2C ligand replacement to prevent colorectal cancer

ES Blomain, AM Pattison, SA Waldman - Cancer biology & therapy, 2016 - Taylor & Francis
Despite advances in screening and prevention strategies, colorectal cancer (CRC) remains
the second-leading cause of cancer-related death in the United States. Given this continued …

An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer

JA Rappaport, SA Waldman - Expert review of clinical …, 2020 - Taylor & Francis
Introduction: Colorectal cancer remains the second leading cause of cancer death in the
United States, underscoring the need for novel therapies. Despite the successes of new …

Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential

AA Entezari, AE Snook, SA Waldman - Expert opinion on …, 2021 - Taylor & Francis
Introduction Gastrointestinal (GI) cancers account for the second leading cause of cancer-
related deaths in the United States. Guanylyl cyclase C (GUCY2C) is an intestinal signaling …

Obesity-induced colorectal cancer is driven by caloric silencing of the guanylin–GUCY2C paracrine signaling axis

JE Lin, F Colon-Gonzalez, E Blomain, GW Kim, A Aing… - Cancer research, 2016 - AACR
Obesity is a well-known risk factor for colorectal cancer but precisely how it influences risks
of malignancy remains unclear. During colon cancer development in humans or animals …

Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer

A Caspi, AA Entezari, M Crutcher, AE Snook… - Personalized …, 2022 - Taylor & Francis
Colorectal cancer remains a major cause of mortality in the USA, despite advances in
prevention and screening. Existing therapies focus primarily on generic treatment such as …

Colorectal cancer is a paracrine deficiency syndrome amenable to oral hormone replacement therapy

P Li, JE Lin, AE Snook, AV Gibbons… - Clinical and …, 2008 - Wiley Online Library
The most commonly lost gene products in colorectal carcinogenesis include the paracrine
hormones guanylin and uroguanylin, the endogenous ligands for guanylyl cyclase C (GCC) …